Approved for Add-on maintenance treatment of moderate-to-severe asthma in patients aged 6 months and older, Maintenance treatment of moderate-to-severe atopic dermatitis, Maintenance treatment of chronic rhinosinusitis with nasal polyps. Dupilumab is a human monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by blocking the IL-4 receptor alpha subunit.…
Loading full data from Know Your Drugs Institute…